Project Grant R35HL183468
Award Date 8/1/26
Completion Date 7/31/33
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $756,607 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research leveraging nutrient sensing and lysosomal degradative capacity in macrophages as a therapeutic approach to cardiovascular disease. The project addresses atherosclerosis, the underlying cause of myocardial infarction, strokes, and heart failure, by investigating dysfunction in the autophagy-lysosome system...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $625,035 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the molecular mechanisms of mitochondrial calcium exchange in the heart. The research addresses mitochondrial calcium overload, which triggers cell death and tissue damage during ischemia-reperfusion injury—a secondary phase of cardiac damage that can account for up to 50 percent of final infarct...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $577,065 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the roles of endoplasmic reticulum stress in calcium-dependent cardiac arrhythmias. The research addresses how endoplasmic reticulum stress response contributes to acquired cardiovascular diseases with high arrhythmic risk, particularly those involving hyperactivity of the ryanodine receptor (RYR2), the...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- The National Heart, Lung and Blood Institute awarded the University of Washington $233,250 under CFDA 93.837 (Cardiovascular Diseases Research) on June 18, 2026, to conduct AI-guided structural biology research on CAV1.2, an L-type calcium channel critical to cardiac contraction and excitation-coupling in the heart. The research will develop an artificial-intelligence-informed platform for structural biology of the CAV1.2 C-terminal domain (CTD), a 571-residue segment whose three-dimensional...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 15, 2026, for Project Grant R03HL185264 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the mechanisms of CAV1.2 dysregulation in hypertension. CAV1.2, a voltage-activated calcium channel essential for blood pressure regulation, is abnormally active in spontaneously hypertensive rats and contributes to excessive...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.368 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanosensitive signaling mechanisms that support endothelial cell resilience in the context of cardiovascular disease treatment. The research elucidates a mechanosensitive signaling domain in endothelial cells and tests how TRPV4-mediated calcium signaling promotes vascular resilience....
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $1,384,453 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the non-canonical roles of NIPBL in cardiomyocytes. The research addresses a gap in understanding why heterozygous NIPBL mutations—which account for over 60 percent of Cornelia de Lange Syndrome (CDLS) cases—lead to congenital heart disease or decreased cardiac function in at least 30 percent of CDLS...
- The National Heart, Lung, and Blood Institute awarded Michigan State University (Henry Ford Health+Michigan State University Health Sciences) $466,362 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the mechanisms by which mitochondrial calcium overload impairs cellular energy metabolism. The project uses cryo-electron microscopy and computational physiology to investigate how calcium sequestration regulates oxidative metabolism across multiple...